Roberto Pacheco Coronado, MD
Interventional Cardiology · Washington, MONPI 1194982892
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 165 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $861 and has fallen 71.8% since, to $243 in 2025. That places this record below the midpoint for interventional cardiology clinicians in MO, where the typical reported total is $10,448.
Across 165 payments — averaging $20.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$594
- Boehringer Ingelheim$376
- Johnson & Johnson$329
- Amgen$315
- Pfizer$216
- Medtronic$215
- plus $1K from 17 others
Across 338 payments — averaging $1075.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$288K
- Abbott$75K
What the payments were for
- Food & beverage$3,25597%
- Gifts$953%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 31 | $594 |
| Boehringer Ingelheim | 20 | $376 |
| Johnson & Johnson | 20 | $329 |
| Amgen | 20 | $315 |
| Pfizer | 10 | $216 |
| Medtronic(2 entities) | 8 | $215 |
| E.r. Squibb & Sons, L.L.C. | 9 | $159 |
| Boston Scientific | 8 | $149 |
| W. L. Gore & Associates, Inc. | 2 | $134 |
| Novo Nordisk | 7 | $128 |
| Abbott | 7 | $115 |
| Abiomed | 3 | $108 |
| Edwards Lifesciences | 1 | $83 |
| AstraZeneca | 5 | $75 |
| Shockwave Medical, Inc | 3 | $69 |
| Philips North America LLC | 1 | $58 |
| Civica, Inc. | 1 | $53 |
| Regeneron Healthcare Solutions, Inc. | 2 | $43 |
| Welch Allyn | 1 | $42 |
| Angiodynamics, Inc. | 2 | $36 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $21 |
| Teleflex LLC | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $13 |
How this compares
$3,350 in reported general payments places this provider in the 25th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 296 | $236,291 |
| XareltoRivaroxaban | 118 | $104,350 |
| JardianceEmpagliflozin | 85 | $97,217 |
| Repatha SureclickEvolocumab | 51 | $43,175 |
| EntrestoSacubitril/Valsartan | 45 | $33,005 |
| RybelsusSemaglutide | 11 | $10,975 |
| BrilintaTicagrelor | 14 | $8,875 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 78 | $3,485 |
| Metoprolol Succinate | 334 | $2,984 |
| Atorvastatin Calcium | 297 | $2,752 |
| Flecainide Acetate | 70 | $2,728 |
| Rosuvastatin Calcium | 162 | $1,368 |
| Potassium Chloride | 64 | $1,327 |
| Carvedilol | 256 | $1,321 |
| Losartan Potassium | 165 | $1,273 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $216 | $236,291296 claims |
| Johnson & JohnsonXarelto | $329 | $104,350118 claims |
| Boehringer IngelheimJardiance | $376 | $97,21785 claims |
| NovartisEntresto | $594 | $33,00545 claims |
| Novo NordiskRybelsus | $128 | $10,97511 claims |
| AstraZenecaBrilinta | $75 | $8,87514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Washington
- Joshua StolkerWashington$1.2M
- Stephen KuehnWashington$57K
- John LasalaSaint Louis$936K
- Harvey SerotaSaint Louis$752K
- Jasvindar SinghSaint Louis$696K
- Gerald MancusoKansas City$402K
- James GranthamKansas City$357K
- Matthew BunteKansas City$242K
- Alan ZajariasSaint Louis$203K
- Anish ThomasSaint Louis$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.